Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; and medical nutrition under the Nutrasumma brand name, as well as skincare under the Cactus brand name. In addition, the company offers ZAP-X, an AI radiosurgery robot for intracranial tumors and lesions; Cifu VAD, the fully magnetically levitated ventricular assist device; and AtriCure Bipolar Radiofrequency Ablation Isolator for the treatment of chronic atrial fibrillation. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of Baiyang Pharmaceutical Group Co., Ltd.
Frequently asked questions
What sector does Qingdao Baheal Medical INC. (301015) operate in?
Qingdao Baheal Medical INC. belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is Qingdao Baheal Medical INC. (301015) current stock price?
As of the latest data, Qingdao Baheal Medical INC. stock price is CN¥25.20, with a previous close of CN¥24.08. Qingdao Baheal Medical INC. gained CN¥1.12 in the last trading session, representing a 4.65% increase.
What is Qingdao Baheal Medical INC. (301015) current market capitalization?
Qingdao Baheal Medical INC. market cap is approximately 13.25 billion.
What is Qingdao Baheal Medical INC. (301015) Earnings Per Share (EPS)?
The trailing EPS is CN¥0.96, and the forward EPS is CN¥1.07.
What is Qingdao Baheal Medical INC. (301015) Price-to-Earnings (P/E) ratio?
Qingdao Baheal Medical INC. current P/E ratio is 26.25, with a forward P/E of 23.55.
Does Qingdao Baheal Medical INC. (301015) pay dividends?
Yes. Qingdao Baheal Medical INC. pays annual dividends with an annualized yield of 2.27% and an estimated annual payout of CN¥0.57 per share.
When is the next ex-dividend date for Qingdao Baheal Medical INC. (301015)?
The next ex-dividend date is scheduled for June 01, 2027.
What is Qingdao Baheal Medical INC. (301015) beta (volatility) score?
Qingdao Baheal Medical INC. has a beta of 0.422, indicating lower volatility than the overall market.
